MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with B

Bromocriptine

Bromocriptine 2.5mg tablets

No stability information

Stability notes for Bromocriptine 2.5mg tablets

There are no stability notes for this medicine.

Suppliers (8) of Bromocriptine 2.5mg tablets
Bromocriptine 2.5mg tablets (A A H Pharmaceuticals Ltd)
Bromocriptine 2.5mg tablets (Alliance Healthcare (Distribution) Ltd)
Bromocriptine 2.5mg tablets (Brown & Burk UK Ltd)
Bromocriptine 2.5mg tablets (CST Pharma Ltd)
Bromocriptine 2.5mg tablets (Exeltis UK Ltd)
Bromocriptine 2.5mg tablets (Medihealth (Northern) Ltd)
Bromocriptine 2.5mg tablets (Necessity Supplies Ltd)
Bromocriptine 2.5mg tablets (Phoenix Healthcare Distribution Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.